Deutsche Bank AG Cuts Stake in bluebird bio, Inc. (NASDAQ:BLUE)

Deutsche Bank AG lessened its stake in bluebird bio, Inc. (NASDAQ:BLUE) by 78.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,063 shares of the biotechnology company’s stock after selling 71,892 shares during the period. Deutsche Bank AG owned 0.21% of bluebird bio worth $167,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Regeneron Pharmaceuticals Inc. acquired a new stake in bluebird bio in the fourth quarter worth about $175,000. Institutional investors own 87.43% of the company’s stock.

Wall Street Analysts Forecast Growth

BLUE has been the subject of a number of analyst reports. JPMorgan Chase & Co. raised bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th. Barclays cut their target price on bluebird bio from $40.00 to $8.00 and set an “overweight” rating for the company in a research note on Monday, March 31st. Wall Street Zen began coverage on bluebird bio in a research note on Thursday, May 15th. They issued a “sell” rating for the company. Baird R W cut bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. Finally, Wells Fargo & Company lowered their price target on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, February 24th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $44.60.

bluebird bio Stock Performance

Shares of bluebird bio stock opened at $4.96 on Tuesday. The business has a 50-day moving average of $4.49 and a 200 day moving average of $6.03. bluebird bio, Inc. has a 12 month low of $3.20 and a 12 month high of $28.60. The stock has a market capitalization of $48.57 million, a price-to-earnings ratio of -0.13 and a beta of 0.27. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.